极端囊刺激对耐药焦点的结构性网络特异效应
Yueyang Cheng1,2,3, Di Wang4, Xiaohua Zhang2,3,5,6
1Department of Neurology, Xuanwu Hospital, Capital Medical University, 100053, Beijing, China.
Brain : a journal of neurology
|March 21, 2025
概括
极端囊 (EC) 显示了作为一种新型的药物耐药性的深度脑刺激标的前景. 电脑刺激有效地抑制了大脑连接区域的发作,1赫兹爆发刺激与高频方法相比.
科学领域:
- 神经外科 神经外科
- 发病学 (Epileptology) 是一个专业的学科.
- 计算神经科学是一种神经科学.
背景情况:
- 耐药性带来了挑战,特别是对于那些不适合进行手术的患者.
- 目前对皮下核的深度大脑刺激 (DBS) 有不同的疗效和副作用.
- 新的DBS目标对于改善治疗至关重要.
研究的目的:
- 为了研究极端囊 (EC) 作为一种新型的DBS针对耐药焦点的目标.
- 评估EC刺激对神经活动和性放电的调节效应.
- 探索EC的结构连接及其刺激效应之间的关系.
主要方法:
- 在11名耐药患者的立体电脑图 (SEEG).
- 电极放置在EC中,与发作开始区域相对侧面.
- 欧洲共同体的结构和有效连接性分析.
- 在不同频率 (5-145 Hz) 和 1 Hz 爆发模式下循环刺激 EC.
- 评估神经同步,间脉冲放电和波纹.
主要成果:
- 欧洲共同体的有效连接与其结构性网络保持一致.
- 电电刺激效应 (同步/脱同步) 是特定于频率的.
- 高频EC刺激抑制了结构连接的皮质区域 (轨道前叶,胰岛等) 的性泄漏. ) 的情况.
- 1Hz爆发刺激显示了与传统高频刺激相比的可比抑制效果.
结论:
- 欧洲共同体是来自连接的皮质区域的焦点的有希望的DBS目标.
- 刺激效应受到欧洲共同体结构连接的约束.
- 像1Hz爆发这样的替代刺激方法具有治疗潜力.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
8.9K
09:51Recording Synaptic Plasticity in Acute Hippocampal Slices Maintained in a Small-volume Recycling-, Perfusion-, and Submersion-type Chamber System
Published on: January 1, 2018
11.5K
相关概念视频
01:20Desensitization and Tachyphylaxis
1.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
207
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
207